Joseph Carroll
Comptroller/Controller/Auditor chez RENOVACOR, INC.
Profil
Joseph Carroll is currently working as the Secretary, Chief Accounting Officer & Senior VP at Renovacor, Inc. Prior to his current position, he worked as the Associate Director-Finance at Idera Pharmaceuticals, Inc. from 2017 to 2021.
Mr. Carroll completed his undergraduate degree at West Chester University of Pennsylvania.
Postes actifs de Joseph Carroll
| Sociétés | Poste | Début |
|---|---|---|
| RENOVACOR, INC. | Comptroller/Controller/Auditor | 17/06/2022 |
Anciens postes connus de Joseph Carroll
| Sociétés | Poste | Fin |
|---|---|---|
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Corporate Officer/Principal | 01/06/2021 |
Formation de Joseph Carroll
| West Chester University of Pennsylvania | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Renovacor, Inc.
 Renovacor, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a clinical stage gene therapy company. It researches and develops AAV-based gene therapies for BAG3 gene mutation-associated diseases. Its therapeutic focus is on cardiovascular diseases. The company was founded by Arthur Michael Feldman on June 7, 2013 and is headquartered in Cambridge, MA. | Health Technology |
